Gain Therapeutics (GANX) PT Lowered to $9 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts GANX Hot Sheet
Price: $1.57 -4.27%
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
7 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Gain Therapeutics (NASDAQ: GANX) to $9.00 (from $10.00) while maintaining a Buy rating.
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $220 at BMO Capital
- Schrodinger (SDGR) PT Raised to $30 at BMO Capital
- Amgen (AMGN) PT Lowered to $415 at BMO Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
